Tango Operating Cash Flow Per Share vs Free Cash Flow Yield Analysis

TNGX Stock

USD 3.10 0.21 6.34%

Tango Therapeutics financial indicator trend analysis is much more than just breaking down Tango Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tango Therapeutics is a good investment. Please check the relationship between Tango Therapeutics Operating Cash Flow Per Share and its Free Cash Flow Yield accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Operating Cash Flow Per Share vs Free Cash Flow Yield

Operating Cash Flow Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tango Therapeutics Operating Cash Flow Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have totally related.

The correlation between Tango Therapeutics' Operating Cash Flow Per Share and Free Cash Flow Yield is 0.99. Overlapping area represents the amount of variation of Operating Cash Flow Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Tango Therapeutics, assuming nothing else is changed. The correlation between historical values of Tango Therapeutics' Operating Cash Flow Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Cash Flow Per Share of Tango Therapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Operating Cash Flow Per Share i.e., Tango Therapeutics' Operating Cash Flow Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Tango Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tango Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.At this time, Tango Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 954.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 22.1 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	95.2M	135.9M	150.7M	98.9M
Cost Of Revenue	2.0M	4.0M	115.2M	121.0M

Total Operating Expenses Cost Of Revenue

Tango Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue
Total Assets		0.61	-0.84	0.92	0.98	0.92	0.94	0.64	-0.65	-0.85	0.96	0.89	0.63	-0.26	0.06	1.0	0.95	1.0	0.92	0.83	0.98	0.92	1.0	0.98	-0.84	-0.75
Short Long Term Debt Total	0.61		-0.32	0.77	0.57	0.61	0.61	1.0	0.16	-0.82	0.71	0.23	1.0	0.5	-0.12	0.53	0.82	0.6	0.58	0.9	0.73	0.62	0.54	0.71	-0.17	-0.37
Other Current Liab	-0.84	-0.32		-0.82	-0.74	-0.93	-0.66	-0.34	0.57	0.66	-0.78	-0.72	-0.34	0.64	-0.56	-0.85	-0.73	-0.87	-0.95	-0.48	-0.75	-0.93	-0.85	-0.79	0.75	0.64
Total Current Liabilities	0.92	0.77	-0.82		0.85	0.93	0.82	0.8	-0.33	-0.88	0.97	0.65	0.79	-0.1	0.22	0.9	0.95	0.94	0.96	0.88	0.92	0.97	0.9	0.93	-0.61	-0.6
Total Stockholder Equity	0.98	0.57	-0.74	0.85		0.85	0.97	0.6	-0.71	-0.82	0.92	0.93	0.6	-0.21	-0.1	0.98	0.92	0.97	0.83	0.82	0.97	0.84	0.98	0.96	-0.87	-0.77
Other Liab	0.92	0.61	-0.93	0.93	0.85		0.77	0.63	-0.48	-0.82	0.9	0.72	0.63	-0.37	0.4	0.92	0.91	0.94	0.98	0.72	0.91	0.98	0.92	0.93	-0.69	-0.64
Net Tangible Assets	0.94	0.61	-0.66	0.82	0.97	0.77		0.64	-0.62	-0.88	0.88	0.88	0.64	-0.08	-0.24	0.93	0.91	0.92	0.75	0.84	0.95	0.77	0.93	0.94	-0.87	-0.85
Property Plant And Equipment Net	0.64	1.0	-0.34	0.8	0.6	0.63	0.64		0.12	-0.84	0.74	0.27	1.0	0.48	-0.13	0.57	0.84	0.63	0.6	0.92	0.76	0.64	0.58	0.74	-0.21	-0.4
Net Debt	-0.65	0.16	0.57	-0.33	-0.71	-0.48	-0.62	0.12		0.24	-0.48	-0.91	0.13	0.65	0.05	-0.7	-0.4	-0.63	-0.46	-0.22	-0.53	-0.44	-0.7	-0.54	0.86	0.54
Retained Earnings	-0.85	-0.82	0.66	-0.88	-0.82	-0.82	-0.88	-0.84	0.24		-0.84	-0.61	-0.83	-0.06	0.04	-0.81	-0.94	-0.84	-0.79	-0.86	-0.91	-0.81	-0.81	-0.91	0.64	0.82
Accounts Payable	0.96	0.71	-0.78	0.97	0.92	0.9	0.88	0.74	-0.48	-0.84		0.76	0.74	-0.1	0.08	0.94	0.95	0.97	0.92	0.9	0.94	0.94	0.95	0.94	-0.7	-0.61
Cash	0.89	0.23	-0.72	0.65	0.93	0.72	0.88	0.27	-0.91	-0.61	0.76		0.27	-0.46	-0.1	0.92	0.72	0.87	0.7	0.57	0.82	0.7	0.91	0.82	-0.96	-0.76
Non Current Assets Total	0.63	1.0	-0.34	0.79	0.6	0.63	0.64	1.0	0.13	-0.83	0.74	0.27		0.49	-0.13	0.57	0.83	0.63	0.6	0.92	0.75	0.64	0.57	0.74	-0.2	-0.39
Non Currrent Assets Other	-0.26	0.5	0.64	-0.1	-0.21	-0.37	-0.08	0.48	0.65	-0.06	-0.1	-0.46	0.49		-0.63	-0.33	-0.02	-0.29	-0.38	0.31	-0.11	-0.33	-0.33	-0.15	0.52	0.27
Other Assets	0.06	-0.12	-0.56	0.22	-0.1	0.4	-0.24	-0.13	0.05	0.04	0.08	-0.1	-0.13	-0.63		0.08	0.02	0.13	0.43	-0.22	-0.01	0.39	0.08	0.04	0.06	0.14
Cash And Short Term Investments	1.0	0.53	-0.85	0.9	0.98	0.92	0.93	0.57	-0.7	-0.81	0.94	0.92	0.57	-0.33	0.08		0.92	0.99	0.91	0.78	0.96	0.91	1.0	0.97	-0.87	-0.75
Common Stock Shares Outstanding	0.95	0.82	-0.73	0.95	0.92	0.91	0.91	0.84	-0.4	-0.94	0.95	0.72	0.83	-0.02	0.02	0.92		0.95	0.88	0.92	0.99	0.9	0.92	0.99	-0.68	-0.71
Short Term Investments	1.0	0.6	-0.87	0.94	0.97	0.94	0.92	0.63	-0.63	-0.84	0.97	0.87	0.63	-0.29	0.13	0.99	0.95		0.94	0.82	0.97	0.95	0.99	0.98	-0.83	-0.73
Non Current Liabilities Total	0.92	0.58	-0.95	0.96	0.83	0.98	0.75	0.6	-0.46	-0.79	0.92	0.7	0.6	-0.38	0.43	0.91	0.88	0.94		0.72	0.87	1.0	0.91	0.9	-0.69	-0.61
Other Current Assets	0.83	0.9	-0.48	0.88	0.82	0.72	0.84	0.92	-0.22	-0.86	0.9	0.57	0.92	0.31	-0.22	0.78	0.92	0.82	0.72		0.89	0.75	0.79	0.87	-0.48	-0.52
Other Stockholder Equity	0.98	0.73	-0.75	0.92	0.97	0.91	0.95	0.76	-0.53	-0.91	0.94	0.82	0.75	-0.11	-0.01	0.96	0.99	0.97	0.87	0.89		0.89	0.96	1.0	-0.77	-0.76
Total Liab	0.92	0.62	-0.93	0.97	0.84	0.98	0.77	0.64	-0.44	-0.81	0.94	0.7	0.64	-0.33	0.39	0.91	0.9	0.95	1.0	0.75	0.89		0.91	0.91	-0.68	-0.61
Total Current Assets	1.0	0.54	-0.85	0.9	0.98	0.92	0.93	0.58	-0.7	-0.81	0.95	0.91	0.57	-0.33	0.08	1.0	0.92	0.99	0.91	0.79	0.96	0.91		0.97	-0.87	-0.75
Common Stock	0.98	0.71	-0.79	0.93	0.96	0.93	0.94	0.74	-0.54	-0.91	0.94	0.82	0.74	-0.15	0.04	0.97	0.99	0.98	0.9	0.87	1.0	0.91	0.97		-0.78	-0.76
Property Plant Equipment	-0.84	-0.17	0.75	-0.61	-0.87	-0.69	-0.87	-0.21	0.86	0.64	-0.7	-0.96	-0.2	0.52	0.06	-0.87	-0.68	-0.83	-0.69	-0.48	-0.77	-0.68	-0.87	-0.78		0.87
Current Deferred Revenue	-0.75	-0.37	0.64	-0.6	-0.77	-0.64	-0.85	-0.4	0.54	0.82	-0.61	-0.76	-0.39	0.27	0.14	-0.75	-0.71	-0.73	-0.61	-0.52	-0.76	-0.61	-0.75	-0.76	0.87

Click cells to compare fundamentals

Tango Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tango Operating Cash Flow Per Share vs Free Cash Flow Yield Analysis

Operating Cash Flow Per Share vs Free Cash Flow Yield

Operating Cash Flow Per Share vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Operating Cash Flow Per Share

Free Cash Flow Yield

Tango Therapeutics fundamental ratios Correlations

Tango Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Tango Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Property Plant Equipment	- 0.96	Cash
Non Current Liabilities Total	- 0.95	Other Current Liab
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Total Liab	- 0.93	Other Current Liab
Other Liab	- 0.93	Other Current Liab
Common Stock	- 0.91	Retained Earnings